English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
抽象的な
Immuno-oncology in Breast Cancer Early Promise
Stefan Gluck
According to data published in 2013, breast cancer (BrCa) is not a disease that harbors high mutational load; nevertheless, it seems that triple negative (TN) BrCa which by itself is a heterogenous group may show much higher rates of mutations than hormone receptor (HR) positive BrCa. These mutations in turn might lead to a higher level of neoantigens which are antigenic and can induce an immune response in the host. This concept, has led investigators to design several clinical trials using immune checkpoint inhibitors (ICI) in early (ECB) and metastatic (MBC) BrCa. Unlike in other cancers, there are no ICI approved in this space yet. Several trials in EBC and MBC using ICI in combination will be reported this year which will hopefully result in advancing therapy and improving patients’ outcomes.